Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06362759
Other study ID # TOUR006-C01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 15, 2024
Est. completion date February 2026

Study information

Verified date June 2024
Source Tourmaline Bio, Inc.
Contact Tourmaline Bio
Phone 347-773-2627
Email clinicaltrialinquiries@tourmalinebio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 in participants with chronic kidney disease and elevated hs-CRP.


Description:

Previous clinical studies have suggested that IL-6-driven inflammation plays a key role in the pathogenesis of cardiovascular diseases including atherosclerotic cardiovascular disease (ASCVD) and heart failure. This Phase 2 study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006, a fully human monoclonal antibody against IL-6. TOUR006 binds the IL-6 cytokine and inhibits downstream IL-6 signaling, thereby reducing the pharmacodynamic marker, hs-CRP.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date February 2026
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years at time of ICF signature. - Serum hs-CRP level =2.0 mg/L and <15 mg/L - Diagnosis of chronic kidney disease, eGFR =15 and <60 mL/min/1.73 m2 - Received COVID-19 vaccine at least 30 days prior to the Screening visit, per participant verbal attestation. - Agreement to comply with contraception and reproduction restrictions Exclusion Criteria: - Clinical evidence or suspicion of active infection - Current or recent COVID-19 infection within 30 days - Serious infection within 12 months - Any history of a serious opportunistic infection - Known history of immunodeficiency - History of gastrointestinal ulceration or perforation - History of active diverticulitis, active inflammatory bowel disease, or GI abscess within 12 months - History of GI bleeding requiring hospitalization and/or transfusion within 6 months - New York Heart Association Class III or IV congestive heart failure and/or hospitalization for heart failure exacerbation within 6 months - Acute coronary syndrome, stroke, transient ischemic attack, or other thrombotic or thromboembolic event, or arterial revascularization procedure within 6 months

Study Design


Intervention

Drug:
TOUR006 - 50 MG
TOUR006 50 MG
TOUR006 - 25 MG
TOUR006 25 MG
TOUR006 - 15 MG
TOUR006 15 MG
Other:
Placebo
Placebo

Locations

Country Name City State
United States Site - 0101 Birmingham Alabama
United States Site - 0110 Charlotte North Carolina
United States Site - 0117 Fargo North Dakota
United States Site - 0102 Fort Mill South Carolina
United States Site - 0103 Greenville South Carolina
United States Site - 0105 Houston Texas
United States Site - 0108 Knoxville Tennessee
United States Site - 0111 Lampasas Texas
United States Site - 0123 Las Vegas Nevada
United States Site - 0109 Manassas Virginia
United States Site - 0127 Marion Ohio
United States Site - 0104 Phoenix Arizona
United States Site - 0116 Rapid City South Dakota
United States Site - 0107 San Antonio Texas
United States Site - 0125 San Dimas California
United States Site - 0121 Wauwatosa Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Tourmaline Bio, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the effects of TOUR006 compared with placebo on hs-CRP Evaluates the change from baseline in hs-CRP comparing TOUR006 and placebo 90 days
Secondary Evaluate the effects of TOUR006 compared with placebo on hs-CRP Evaluates the change from baseline in hs-CRP comparing TOUR006 and placebo 180 days
Secondary Evaluate the pharmacokinetics by measuring serum concentrations of TOUR006 Evaluates the serum concentrations of TOUR006 over time Baseline through Day 365
Secondary Evaluate the safety and tolerability of TOUR006 in participants with elevated cardiovascular risk and CKD Evaluates the percentage of participants with treatment emergent adverse events and serious adverse events 365 days
See also
  Status Clinical Trial Phase
Recruiting NCT06386172 - Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm N/A
Recruiting NCT04910867 - APOL1 Genetic Testing Program for Living Donors N/A
Completed NCT03434145 - Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases N/A
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Terminated NCT05022329 - COVID-19 Vaccine Boosters in Patients With CKD Phase 2/Phase 3
Not yet recruiting NCT04925661 - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia Phase 1
Recruiting NCT04961164 - Resistant Starch Prebiotic Effects in Chronic Kidney Disease N/A
Completed NCT05015647 - Low Protein Diet in CKD Patients at Risk of Malnutrition N/A
Completed NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Completed NCT04363554 - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Recruiting NCT04831021 - Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role? N/A
Terminated NCT04877847 - Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury N/A
Recruiting NCT04422652 - Combination of Novel Therapies for CKD Comorbid Depression Phase 2
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Not yet recruiting NCT06330480 - Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease N/A
Recruiting NCT03176862 - Left Ventricular Fibrosis in Chronic Kidney Disease N/A
Terminated NCT02539680 - Intestinal Phosphate Transporter Expression in CKD Patients N/A